Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM +20.58%36 Debt-to-Equity is 0.07 as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 970 Biotechnology companies, BioStem Technologies ranks better than 65.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioStem Technologies's Debt-to-Equity or its related term are showing as below:
BSEM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.52 Med: -1.03 Max: 1.1
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of BioStem Technologies was 1.10. The lowest was -3.52. And the median was -1.03.
BSEM's Debt-to-Equity is ranked better than 65.88% of 970
companies
in the Biotechnology industry
Industry Median: 0.16
vs BSEM: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioStem Technologies Debt-to-Equity Related Terms
BioStem Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs RNTX, SPRO, ACRV: Debt-to-Equity Comparison
For the Biotechnology subindustry, BioStem Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a Debt-to-Equity of 0.07 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #331 out of 970 companies in the Biotechnology industry, placing it in the top 34.1%.
Is BioStem Technologies' Debt-to-Equity too high?
BioStem Technologies' current Debt-to-Equity is 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. BioStem Technologies' value of 0.07 is 56.3% below this industry median. Based on the distribution chart, BioStem Technologies ranks #331 out of 970 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Debt-to-Equity compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #331 out of 970 companies for Debt-to-Equity. This puts BioStem Technologies in the upper half of its industry. The industry median Debt-to-Equity is 0.16. BioStem Technologies' value of 0.07 is 56.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Debt-to-Equity of 0.07 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Debt-to-Equity is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Debt-to-Equity of 0.07. The current Debt-to-Equity is 0.07 and 56.3% below the Biotechnology industry median of 0.16. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Debt-to-Equity is 0.07 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
